Display options
Cite
Frey R, Saleh S, Becker C, et al. Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ. 2016;6:S58-65doi: 10.1086/685019.
Frey, R., Saleh, S., Becker, C., & Mück, W. (2016). Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulmonary circulation, 6S58-65. https://doi.org/10.1086/685019
Frey, Reiner, et al. "Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)." Pulmonary circulation vol. 6 (2016): S58-65. doi: https://doi.org/10.1086/685019
Frey R, Saleh S, Becker C, Mück W. Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ. 2016 Mar;6:S58-65. doi: 10.1086/685019. PMID: 27162629; PMCID: PMC4860529.
Copy Download .nbib Format: NLM
Share it on

Pulm Circ. 2016 Mar;6:S58-65. doi: 10.1086/685019.

Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Pulmonary circulation

Reiner Frey, Soundos Saleh, Corina Becker, Wolfgang Mück

Affiliations

  1. Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.

PMID: 27162629 PMCID: PMC4860529 DOI: 10.1086/685019

Abstract

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). This randomized, double-blind, placebo-controlled study investigated the pharmacokinetics of riociguat and its metabolite M1 in young (18-45 years) and elderly (64.5-80 years) healthy volunteers of both sexes to assist planning of the dose regimens for clinical trials. The data were also used to draw comparisons with the effects of age and sex on riociguat pharmacokinetics in patients with PAH and CTEPH from the riociguat phase 3 trials, PATENT and CHEST. Volunteers received an oral dose of either riociguat 2.5 mg or placebo, and the concentrations of riociguat and M1 in blood and urine samples were determined using mass spectrometry. In elderly healthy volunteers, overall riociguat and M1 exposure tended to be higher than in young healthy volunteers (P > 0.05), partly because of reduced renal clearance (approximately 28% reduction) and differences in body weight. Although the mean maximum concentrations of riociguat and M1 were significantly higher in women than in men (35% and 50% higher, respectively), total exposure was similar. Despite differences in riociguat and M1 pharmacokinetics, riociguat was well tolerated with a comparable safety profile across all subgroups, suggesting that differences in drug exposure due to age or sex were not sufficient to warrant a dose adjustment in clinical trials. Furthermore, similar pharmacokinetics were observed in patients with PAH and CTEPH. However, particular care should be exercised during individual dose titration of riociguat in elderly patients.

Keywords: chronic thromboembolic pulmonary hypertension; drug exposure; pulmonary arterial hypertension

References

  1. Chest. 2012 Aug;142(2):448-56 - PubMed
  2. N Engl J Med. 2013 Jul 25;369(4):330-40 - PubMed
  3. J Biomed Biotechnol. 2011;2011:187103 - PubMed
  4. Circulation. 2011 Nov 1;124(18):1973-81 - PubMed
  5. Eur Respir J. 2012 Apr;39(4):945-55 - PubMed
  6. Chest. 2010 Feb;137(2):376-87 - PubMed
  7. Clin Pharmacol Ther. 2008 Sep;84(3):417-23 - PubMed
  8. Proc Natl Acad Sci U S A. 1977 Aug;74(8):3203-7 - PubMed
  9. J Clin Pharmacol. 2008 Aug;48(8):926-34 - PubMed
  10. Circulation. 2011 May 24;123(20):2263-73 - PubMed
  11. Nat Rev Drug Discov. 2006 Sep;5(9):755-68 - PubMed
  12. Eur Respir J. 2008 Oct;32(4):881-91 - PubMed
  13. Eur Heart J. 2016 Jan 1;37(1):67-119 - PubMed
  14. Eur Respir J. 2015 May;45(5):1303-13 - PubMed
  15. Exp Gerontol. 2003 Aug;38(8):843-53 - PubMed
  16. Circulation. 2009 Apr 28;119(16):2250-94 - PubMed
  17. Clin Pharmacokinet. 2003;42(2):107-21 - PubMed
  18. N Engl J Med. 2013 Jul 25;369(4):319-29 - PubMed
  19. Drug Metab Rev. 2009;41(2):67-76 - PubMed
  20. Handb Exp Pharmacol. 2009;(191):277-308 - PubMed
  21. Clin Res Cardiol. 2007 Aug;96(8):527-41 - PubMed
  22. Eur Respir J. 2015 May;45(5):1293-302 - PubMed
  23. Int J Cardiol. 2013 Sep 30;168(2):871-80 - PubMed
  24. Ann Intern Med. 1991 Sep 1;115(5):343-9 - PubMed

Publication Types